AR023818A1 - Sistema de activacion de cimogeno - Google Patents
Sistema de activacion de cimogenoInfo
- Publication number
- AR023818A1 AR023818A1 ARP000102081A ARP000102081A AR023818A1 AR 023818 A1 AR023818 A1 AR 023818A1 AR P000102081 A ARP000102081 A AR P000102081A AR P000102081 A ARP000102081 A AR P000102081A AR 023818 A1 AR023818 A1 AR 023818A1
- Authority
- AR
- Argentina
- Prior art keywords
- cytogen
- precursor
- activation
- catalytic activity
- protease gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Describimos las secuencias de ADN que codifican un sistema de vector de expresion que permitirá, a través de proteolisis limitada, la activacion de unprecursor de cimogeno (S1) de proteasas de serina en un modo altamente controlado y reproducible. Laproteína expresada procesada, una vez activada, es logradaen una forma docil para medir la actividad catalítica. Esta actividad catalítica de la forma activada, es con frecuencia una representacion más precisa delproducto del gen de proteasa S1 relativo al precursor de cimogeno no procesado. Por eso, esta serie de construcciones de activacion de cimogeno representa unsistema significativo para el análisis y caracterizacion de los productos del gen de proteasa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30316299A | 1999-04-30 | 1999-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023818A1 true AR023818A1 (es) | 2002-09-04 |
Family
ID=23170790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000102081A AR023818A1 (es) | 1999-04-30 | 2000-04-28 | Sistema de activacion de cimogeno |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1173590A4 (es) |
JP (1) | JP2003531567A (es) |
AR (1) | AR023818A1 (es) |
AU (1) | AU4239600A (es) |
CA (1) | CA2372907A1 (es) |
WO (1) | WO2000066709A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006271285A (ja) * | 2005-03-30 | 2006-10-12 | National Institute Of Information & Communication Technology | 改良型haタグ及び改良型haタグを用いたスクリーニング方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200340A (en) * | 1987-05-22 | 1993-04-06 | Zymogenetics, Inc. | Thrombin-activated tissue plasminogen activators |
US5504001A (en) * | 1987-11-25 | 1996-04-02 | Zymogenetics, Inc. | Hybrid plasminogen activator |
US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
US5196322A (en) * | 1987-12-28 | 1993-03-23 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
US5342762A (en) * | 1991-01-03 | 1994-08-30 | Wisconsin Alumni Research Foundation | Fibronectin purification vector |
ATE242330T1 (de) * | 1993-01-15 | 2003-06-15 | Inst Genetics Llc | Klonierung von enterokinase und verfahren zu deren verwendung |
DK82893D0 (da) * | 1993-07-08 | 1993-07-08 | Novo Nordisk As | Peptid |
US6277618B1 (en) * | 1996-06-06 | 2001-08-21 | Roche Diagnostics Gmbh | Recombinant blood-coagulation proteases |
AU742794B2 (en) * | 1997-04-25 | 2002-01-10 | Sembiosys Genetics Inc. | Method for cleavage of fusion proteins |
-
2000
- 2000-04-13 AU AU42396/00A patent/AU4239600A/en not_active Abandoned
- 2000-04-13 WO PCT/US2000/009973 patent/WO2000066709A2/en not_active Application Discontinuation
- 2000-04-13 EP EP00922167A patent/EP1173590A4/en not_active Withdrawn
- 2000-04-13 CA CA002372907A patent/CA2372907A1/en not_active Abandoned
- 2000-04-13 JP JP2000615734A patent/JP2003531567A/ja active Pending
- 2000-04-28 AR ARP000102081A patent/AR023818A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1173590A2 (en) | 2002-01-23 |
AU4239600A (en) | 2000-11-17 |
CA2372907A1 (en) | 2000-11-09 |
EP1173590A4 (en) | 2003-01-15 |
JP2003531567A (ja) | 2003-10-28 |
WO2000066709A9 (en) | 2002-08-29 |
WO2000066709A2 (en) | 2000-11-09 |
WO2000066709A3 (en) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cameron et al. | Polyarginines are potent furin inhibitors | |
York et al. | Tripeptidyl peptidase II is the major peptidase needed to trim long antigenic precursors, but is not required for most MHC class I antigen presentation | |
Lu et al. | Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes | |
Remacle et al. | Substrate cleavage analysis of furin and related proprotein convertases: a comparative study | |
Suzuki et al. | Modulation of cellular signals by calpain. | |
Kridel et al. | Substrate hydrolysis by matrix metalloproteinase-9 | |
Stöcker et al. | Implications of the three‐dimensional structure of astacin for the structure and function of the astacin family of zinc‐endopeptidases | |
Turk et al. | Determination of protease cleavage site motifs using mixture-based oriented peptide libraries | |
St. Hilaire et al. | Fluorescence-quenched solid phase combinatorial libraries in the characterization of cysteine protease substrate specificity | |
Zhou et al. | Proteolytic processing in the secretory pathway | |
Doucet et al. | Broad coverage identification of multiple proteolytic cleavage site sequences in complex high molecular weight proteins using quantitative proteomics as a complement to edman sequencing | |
DK0771209T3 (da) | Hidtil ukendte peptider | |
NO981169L (no) | Pneumokokkiske gener, deler derav, ekspresjonsprodukter fra disse samt anvendelse av slike gener, deler og produkter | |
Cao et al. | Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase | |
WO2001016289A3 (en) | Zymogen activation system | |
Chen et al. | Synthetic and biological approaches to map substrate specificities of proteases | |
Fugere et al. | Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences | |
TR199902751T2 (xx) | Proteaz inhibit�rleri. | |
Zamolodchikova et al. | Activation of recombinant proenteropeptidase by duodenase | |
Hattori et al. | BACE1 interacts with nicastrin | |
Mzhavia et al. | Characterization of endothelin-converting enzyme-2: Implication for a role in the nonclassical processing of regulatory peptides | |
ID23393A (id) | Produk makanan beku | |
Nguyen et al. | Protease specificity profiling in a pipet tip using “Charge-Synchronized” proteome-derived peptide libraries | |
AR023818A1 (es) | Sistema de activacion de cimogeno | |
Zelanis et al. | Deep profiling of the cleavage specificity and human substrates of snake venom metalloprotease HF3 by proteomic identification of cleavage site specificity (PICS) using proteome derived peptide libraries and terminal amine isotopic labeling of substrates (TAILS) N-terminomics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |